Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Free Report) was the recipient of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 13,120,000 shares, an increase of 150.4% from the October 31st total of 5,240,000 shares. Currently, 20.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,310,000 shares, the days-to-cover ratio is presently 5.7 days.
Tenaya Therapeutics Stock Performance
Shares of Tenaya Therapeutics stock traded up $0.28 during midday trading on Friday, hitting $3.57. 4,624,728 shares of the company traded hands, compared to its average volume of 1,027,089. The stock has a market cap of $282.82 million, a price-to-earnings ratio of -2.48 and a beta of 2.34. The firm’s fifty day moving average price is $2.11 and its 200-day moving average price is $2.85. Tenaya Therapeutics has a 12 month low of $1.61 and a 12 month high of $7.01.
Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.07. Equities research analysts forecast that Tenaya Therapeutics will post -1.35 earnings per share for the current year.
Wall Street Analyst Weigh In
View Our Latest Research Report on TNYA
Institutional Investors Weigh In On Tenaya Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. Synovus Financial Corp acquired a new stake in Tenaya Therapeutics during the 3rd quarter worth approximately $28,000. SG Americas Securities LLC acquired a new stake in Tenaya Therapeutics during the 3rd quarter worth approximately $49,000. The Manufacturers Life Insurance Company boosted its position in Tenaya Therapeutics by 43.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after buying an additional 7,000 shares during the period. Algert Global LLC acquired a new stake in Tenaya Therapeutics during the 2nd quarter worth approximately $74,000. Finally, XTX Topco Ltd boosted its position in Tenaya Therapeutics by 51.2% during the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after buying an additional 16,687 shares during the period. 90.54% of the stock is currently owned by institutional investors and hedge funds.
Tenaya Therapeutics Company Profile
Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
See Also
- Five stocks we like better than Tenaya Therapeutics
- Canada Bond Market Holiday: How to Invest and Trade
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Pros And Cons Of Monthly Dividend Stocks
- 3 Penny Stocks Ready to Break Out in 2025
- Want to Profit on the Downtrend? Downtrends, Explained.
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.